Rein Therapeutics, Inc.

RNTX · Nasdaq · SIC 2834: Pharmaceutical Preparations
160
SEC Filings

Business Summary

Overview and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI01 for an undetermined period of time and are prioritizing LTI03. Our pipeline includes: LTI-03, a peptide, for...

Next Earnings

Q2 FY2026 — expected 2026-09-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionRNTXdiscussed_in_filing Cybersecurity
topic_mentionRNTXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-262025-12-310001193125-26-126385EDGAR98K words
2025-04-072024-12-310000950170-25-051566EDGAR—
2024-04-152023-12-310000950170-24-044508EDGAR—
2023-03-202022-12-310000950170-23-008767EDGAR—
2022-03-282021-12-310000950170-22-004774EDGAR—
2021-03-242020-12-310001564590-21-015115EDGAR—
2020-03-302019-12-310001564590-20-014155EDGAR—
2019-03-292018-12-310001564590-19-010007EDGAR—
2018-04-022017-12-310001564590-18-007403EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-281622EDGAR31K words
2025-08-142025-06-300000950170-25-108836EDGAR—
2025-05-152025-03-310000950170-25-072607EDGAR—
2024-11-142024-09-300000950170-24-127019EDGAR—
2024-08-142024-06-300000950170-24-097199EDGAR—
2024-05-152024-03-310000950170-24-060583EDGAR—
2023-10-132023-09-300000950170-23-053302EDGAR—
2023-08-112023-06-300000950170-23-041839EDGAR—
2023-05-082023-03-310000950170-23-018476EDGAR—
2022-11-012022-09-300000950170-22-020709EDGAR—
2022-08-152022-06-300000950170-22-017372EDGAR—
2022-05-052022-03-310000950170-22-007793EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-020001193125-26-084012EDGAR15K words
2026-02-190001193125-26-059545EDGAR—
2026-01-160001193125-26-015524EDGAR—
2025-12-110001193125-25-316225EDGAR—
2025-11-030001193125-25-261706EDGAR—
2025-10-240001193125-25-250175EDGAR—
2025-10-090001193125-25-235152EDGAR—
2025-09-220001193125-25-210050EDGAR—
2025-09-090001193125-25-198816EDGAR—
2025-08-190001193125-25-183073EDGAR—

160 total filings indexed. 129 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001420565
TickerRNTX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 44553c5997d28a80db4287790516c9baa970f13a4fde5f5d96a024c65b757d92
parent: 1803ce8ff20dc51eab1ceb972c3a7b09275d1b2475f25e2b015f9d37df79e6f8
content hash: 3a6b1ab90aedbd1ffd068f3bf98c59361209e6a63a92b997e582858af3659560
signed: 2026-04-13T04:47:14.311Z
sources: 21 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf